Edap Tms (NASDAQ:EDAP) Raised to Hold at Zacks Investment Research

Zacks Investment Research upgraded shares of Edap Tms (NASDAQ:EDAP) from a sell rating to a hold rating in a report published on Tuesday, Zacks.com reports.

According to Zacks, “EDAP TMS S.A. develops, produces, markets and distributes minimally invasive medical devices, primarily for the treatment of urological diseases. They currently produce and market devices for treatment of benign prostate hyperplasia and urinary tract stones. They are also developing a third range of products for minimally invasive destruction of certain types of tumors. “

Several other equities analysts have also recently weighed in on the stock. ValuEngine raised shares of YY from a sell rating to a hold rating in a research report on Friday, June 7th. HC Wainwright set a $4.00 target price on shares of Uranium Energy and gave the stock a buy rating in a research report on Tuesday, June 11th. Finally, TheStreet cut shares of Timkensteel from a c- rating to a d+ rating in a research report on Monday, June 17th.

NASDAQ EDAP traded down $0.07 during trading hours on Tuesday, hitting $2.64. The company’s stock had a trading volume of 15,310 shares, compared to its average volume of 62,474. Edap Tms has a 52 week low of $1.35 and a 52 week high of $5.42. The stock has a market capitalization of $77.13 million, a P/E ratio of 132.00 and a beta of 1.94. The company has a debt-to-equity ratio of 0.09, a current ratio of 2.40 and a quick ratio of 1.97. The company’s 50-day moving average price is $2.73.

Edap Tms (NASDAQ:EDAP) last announced its quarterly earnings results on Wednesday, May 15th. The medical equipment provider reported $0.01 earnings per share for the quarter, meeting the Thomson Reuters’ consensus estimate of $0.01. Edap Tms had a negative net margin of 0.36% and a negative return on equity of 1.13%. The business had revenue of $11.50 million for the quarter, compared to analysts’ expectations of $13.25 million. On average, research analysts anticipate that Edap Tms will post 0.08 EPS for the current fiscal year.

A hedge fund recently bought a new stake in Edap Tms stock. Hilton Capital Management LLC purchased a new position in Edap Tms SA (NASDAQ:EDAP) during the first quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The fund purchased 25,000 shares of the medical equipment provider’s stock, valued at approximately $75,000. Hilton Capital Management LLC owned 0.09% of Edap Tms at the end of the most recent quarter.

About Edap Tms

EDAP TMS SA, together with its subsidiaries, develops, produces, markets, distributes, and maintains a portfolio of minimally-invasive medical devices for the treatment of urological diseases worldwide. The company operates in two divisions: High Intensity Focused Ultrasound (HIFU), and Urology Devices and Services (UDS).

Featured Article: Intrinsic Value

Get a free copy of the Zacks research report on Edap Tms (EDAP)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Ratings for Edap Tms Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Edap Tms and related companies with MarketBeat.com's FREE daily email newsletter.